| Description | Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α. |
| In vivo | Tafluprost在日常临床实践中显示出显著的降低内眼压(IOP)效果，对各种类型的青光眼和高眼压(OH)患者均无安全隐患，且在任何治疗模式下均具有高效性[1]。添加减量BAK的Tafluprost具有成为优越抗青光眼药物的潜力，这不仅因其降低IOP的效果，还因其良好的角膜安全性能[2]。Tafluprost单次使用瓶装治疗在本研究的3年中有效降低IOP，但正常张力青光眼患者的视野性能恶化了10.3%-13.8%[3]。 |
| Synonyms | MK2452, AFP-168, 他氟前列素 |
| molecular weight | 452.53 |
| Molecular formula | C25H34F2O5 |
| CAS | 209860-87-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 250 mg/mL (552.45 mM) |
| References | 1. Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71. 2. Kumagami, T., et al., Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther, 2014. 30(4): p. 340-5. 3. Inoue, K., A. Tanaka, and G. Tomita, Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol, 2013. 7: p. 1411-6. |
| Citations | 1. Wu S, Liu C, Tang J, et al.Tafluprost promotes axon regeneration after optic nerve crush via Zn2+-mTOR pathway.Neuropharmacology.2023: 109746. |